Drug Profile
Research programme: antibody-drug conjugates - PDL BioPharma
Alternative Names: Anti-TMEFF2 ADC; Anti-TMEFF2-MMAE conjugate; Anti-TMEFF2-monomethyl auristatin E conjugate; Anti-tomoregulin ADC; Anti-tomoregulin-MMAE conjugate; Anti-tomoregulin-monomethyl auristatin E conjugate; Humanised anti-TMEFF2-auristatin E conjugated mAb; Humanised anti-TMEFF2-auristatin E conjugated monoclonal antibody; Humanised anti-tomoregulin-auristatin E conjugated mAb; Humanised anti-tomoregulin-auristatin E conjugated monoclonal antibody; huPr1-vcMMAE; PR1-ADC; Pr1-vc-MMAELatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Developer Seagen
- Class Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 16 Aug 2006 This programme is still in active development